Zobrazeno 1 - 10
of 19
pro vyhledávání: '"NJ Lakhani"'
Autor:
NK Ibrahim, S-C Tang, AJ Brenner, S Kesari, DE Piccioni, CK Anders, JA Carillo, P Chalasani, P Kabos, S Puhalla, AA Garcia, KH Tkaczuk, MS Ahluwalia, NJ Lakhani, P Kumthekar
Publikováno v:
Cancer Research. 77:P1-12
Background: The incidence of CNS metastatic disease in breast cancer patients (pts) seems to have increased in recent years with the improvement of systemic therapy. However, treatment options for CNS metastases have remained limited due to the inabi
Autor:
Lakhani NJ; START Midwest, Grand Rapids, Michigan, United States., Papadopoulos KP; START San Antonio, San Antonio, Texas, United States., Johnson ML; Sarah Cannon Research Instutite, Nashville, TN, United States., Park H; Dana-Farber Cancer Institute, Boston, MA, United States., Wang D; Clinical Trial Office, Detroit, Michigan, United States., Yap TA; The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Dowlati A; University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States., Maki RG; Memorial Sloan Kettering Cancer Center, New York, NY, United States., Ulahannan S; Stephenson Cancer Center, OUHSC, OKC, Oklahoma, United States., Lynce F; Dana-Farber/Harvard Cancer Center, Boston, MA, United States., Kelly K; University of California Davis Comprehensive Cancer Center, Sacramento, United States., Williamson S; University of Kansas Cancer Center, Fairway, Kansas, United States., Malhotra J; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States., Chen S; Regeneron (United States), United States., Gonzalez Ortiz A; Regeneron (United States), United States., Jankovic V; Regeneron (United States), United States., Paccaly A; Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States., Masinde S; Regeneron (United States), United States., Mani J; Regeneron (United States), United States., Lowy I; Regeneron Pharmaceuticals, Inc., New york, Ny, United States., Gullo G; Regeneron (United States), United States., Sims T; Regeneron (United States), Tarrytown, United States., Kroog G; Regeneron (United States), United States.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Oct 18. Date of Electronic Publication: 2024 Oct 18.
Autor:
Lakhani NJ; START Midwest, Grand Rapids, MI, USA. nehal.lakhani@startmidwest.com., Burris H 3rd; Sarah Cannon Research Institute, Nashville, TN, USA., Miller WH Jr; Department of Medicine and Oncology, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, QC, Canada., Huang M; Merck & Co., Inc., Rahway, NJ, USA., Chen LC; Merck & Co., Inc., Rahway, NJ, USA., Siu LL; Princess Margaret Cancer Centre, Toronto, ON, Canada.
Publikováno v:
Investigational new drugs [Invest New Drugs] 2024 Sep 14. Date of Electronic Publication: 2024 Sep 14.
Autor:
Hamid O; The Angeles Clinical and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA., Lewis KD; University of Colorado Denver Cancer Center, Aurora, CO., Weise A; Henry Ford Hospital, Detroit, MI., McKean M; Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, TN., Papadopoulos KP; START, San Antonio, TX., Crown J; St Vincent's University Hospital, Dublin, Ireland., Kim TM; Seoul National University Hospital, Seoul, South Korea., Lee DH; Asan Medical Center, Seoul, South Korea., Thomas SS; University of Florida Health Cancer Center at Orlando Health, Orlando, FL., Mehnert J; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Kaczmar J; MUSC Hollings Cancer Center, Charleston, SC., Lakhani NJ; START Midwest, Grand Rapids, MI., Kim KB; Center for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, San Francisco, CA., Middleton MR; Department of Oncology, NIHR Biomedical Research Centre, Oxford, United Kingdom., Rabinowits G; Miami Cancer Institute/Baptist Health South Florida, Miami, FL., Spira AI; Virginia Cancer Specialists and US Oncology Research, Fairfax, VA., Yushak M; Department of Hematology and Medical Oncology at Emory University School of Medicine, Atlanta, GA., Mehmi I; The Angeles Clinical and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA., Fang F; Regeneron Pharmaceuticals, Inc, Tarrytown, NY., Chen S; Regeneron Pharmaceuticals, Inc, Tarrytown, NY., Mani J; Regeneron Pharmaceuticals, Inc, Tarrytown, NY., Jankovic V; Regeneron Pharmaceuticals, Inc, Tarrytown, NY., Wang F; Regeneron Pharmaceuticals, Inc, Tarrytown, NY., Fiaschi N; Regeneron Pharmaceuticals, Inc, Tarrytown, NY., Brennan L; Regeneron Pharmaceuticals, Inc, Tarrytown, NY., Paccaly A; Regeneron Pharmaceuticals, Inc, Tarrytown, NY., Masinde S; Regeneron Pharmaceuticals, Inc, Tarrytown, NY., Salvati M; Regeneron Pharmaceuticals, Inc, Tarrytown, NY., Fury MG; Regeneron Pharmaceuticals, Inc, Tarrytown, NY., Kroog G; Regeneron Pharmaceuticals, Inc, Tarrytown, NY., Lowy I; Regeneron Pharmaceuticals, Inc, Tarrytown, NY., Gullo G; Regeneron Pharmaceuticals, Inc, Tarrytown, NY.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Aug 20; Vol. 42 (24), pp. 2928-2938. Date of Electronic Publication: 2024 Jun 20.
Autor:
Keller PJ; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Adams EJ; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Wu R; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Côté A; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Arora S; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Cantone N; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Meyer R; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Mertz JA; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Gehling V; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Cui J; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Stuckey JI; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Khanna A; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Zhao F; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Chen Z; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Yu Z; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Cummings RT; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Taimi M; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Lakhani NJ; START Midwest, Grand Rapids, Michigan., Rasco D; South Texas Accelerated Research Therapeutics, San Antonio, Texas., Gutierrez M; Hackensack University Medical Center, Hackensack, New Jersey., Duska L; University of Virginia School of Medicine, Charlottesville, Virginia., Devitt M; University of Virginia School of Medicine, Charlottesville, Virginia., Rippley R; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Levell J; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Truong J; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Wang J; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Sun K; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts., Trojer P; Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts.
Publikováno v:
Cancer research [Cancer Res] 2024 Aug 01; Vol. 84 (15), pp. 2501-2517.
Autor:
Lakhani NJ; START Midwest, Grand Rapids, Michigan., Rasco D; START, San Antonio, Texas., Wang H; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China., Men L; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China., Liang E; Ascentage Pharma Group Inc., Rockville, Maryland., Fu T; Ascentage Pharma Group Inc., Rockville, Maryland., Collins MC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Min P; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China., Yin Y; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Yang D; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.; Ascentage Pharma Group Inc., Rockville, Maryland.; Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China., Zhai Y; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.; Ascentage Pharma Group Inc., Rockville, Maryland.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Feb 01; Vol. 30 (3), pp. 506-521.
Autor:
Subbiah V; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Sarah Cannon Research Institute, Nashville, Tennessee., Chawla SP; Sarcoma Oncology Research Center, Santa Monica, California., Conley AP; Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wilky BA; Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado., Tolcher A; NEXT Oncology, San Antonio, Texas., Lakhani NJ; START Midwest, Michigan., Berz D; Valkyrie Clinical Trials, Los Angeles, California., Andrianov V; Inhibrx, Inc, La Jolla, California., Crago W; Inhibrx, Inc, La Jolla, California., Holcomb M; Inhibrx, Inc, La Jolla, California., Hussain A; Inhibrx, Inc, La Jolla, California., Veldstra C; Inhibrx, Inc, La Jolla, California., Kalabus J; Inhibrx, Inc, La Jolla, California., O'Neill B; Inhibrx, Inc, La Jolla, California., Senne L; Inhibrx, Inc, La Jolla, California., Rowell E; Inhibrx, Inc, La Jolla, California., Heidt AB; Inhibrx, Inc, La Jolla, California., Willis KM; Inhibrx, Inc, La Jolla, California., Eckelman BP; Inhibrx, Inc, La Jolla, California.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Aug 15; Vol. 29 (16), pp. 2988-3003.
Autor:
Garralda E; Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain. Electronic address: egarralda@vhio.net., Sukari A; Medical Oncology, Karmanos Cancer Institute, Detroit., Lakhani NJ; Clinical Research, START Midwest, Grand Rapids., Patnaik A; Clinical Research, START San Antonio, San Antonio., Lou Y; Oncology, Mayo Clinic, Jacksonville, USA., Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Golan T; Gastrointestinal Clinic, Sheba Medical Center, Tel-Aviv University, Tel Aviv., Geva R; Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel., Wermke M; NCT/UCC Early Clinical Trial Unit, Technical University, Dresden, Germany., de Miguel M; Clinical Research, START-HM Sanchinarro Madrid, Madrid, Spain., Palcza J; Clinical Research, Merck & Co., Inc., Rahway., Jha S; Clinical Research, Merck & Co., Inc., Rahway., Chaney M; Clinical Research, Merck & Co., Inc., Rahway., Abraham AK; Clinical Research, Merck & Co., Inc., Rahway., Healy J; Clinical Research, Merck & Co., Inc., Rahway., Falchook GS; Drug Development, Sarah Cannon Research Institute at HealthONE, Denver, USA.
Publikováno v:
ESMO open [ESMO Open] 2022 Dec; Vol. 7 (6), pp. 100639. Date of Electronic Publication: 2022 Dec 06.
Autor:
Borazanci E; HonorHealth, Scottsdale, USA. Electronic address: eborazanci@honorhealth.com., Schram AM; Memorial Sloan Kettering Cancer Center, New York, USA., Garralda E; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain., Brana I; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain., Vieito Villar M; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain., Spreafico A; Princess Margaret Cancer Centre, Toronto, Canada., Oliva M; Princess Margaret Cancer Centre, Toronto, Canada., Lakhani NJ; START Midwest, Grand Rapids, USA., Hoffman K; Northern Biologics, Inc., Toronto, Canada., Hallett RM; Northern Biologics, Inc., Toronto, Canada., Maetzel D; Northern Biologics, Inc., Toronto, Canada., Hua F; Applied BioMath, Concord, USA., Hilbert J; Applied BioMath, Concord, USA., Giblin P; Northern Biologics, Inc., Toronto, Canada., Anido J; Northern Biologics, Inc., Toronto, Canada., Kelly A; Northern Biologics, Inc., Toronto, Canada., Vickers PJ; Northern Biologics, Inc., Toronto, Canada., Wasserman R; Northern Biologics, Inc., Toronto, Canada., Seoane J; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Universitat Autònoma de Barcelona (UAB), CIBERONC, Barcelona., Siu LL; Princess Margaret Cancer Centre, Toronto, Canada., Hyman DM; Memorial Sloan Kettering Cancer Center, New York, USA., Hoff DV; HonorHealth, Scottsdale, USA., Tabernero J; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain; UVic-UCC, IOB-Quiron, Barcelona, Spain.
Publikováno v:
ESMO open [ESMO Open] 2022 Aug; Vol. 7 (4), pp. 100530. Date of Electronic Publication: 2022 Jul 31.
Autor:
Aggarwal C; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA charu.aggarwal@uphs.upenn.edu., Prawira A; Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia., Antonia S; Duke Cancer Institute Center for Cancer Immunotherapy, Durham, North Carolina, USA.; Moffitt Cancer Center, Tampa, Florida, USA., Rahma O; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Tolcher A; NEXT Oncology, San Antonio, Texas, USA.; START-South Texas, San Antonio, Texas, USA., Cohen RB; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Lou Y; Mayo Clinic, Jacksonville, Florida, USA., Hauke R; Nebraska Cancer Specialists, Omaha, Nebraska, USA., Vogelzang N; Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA., P Zandberg D; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA., Kalebasty AR; Norton Cancer Institute, Louisville, Kentucky, USA., Atkinson V; Princess Alexandra Hospital, Woolloongabba, Queensland, Australia., Adjei AA; Mayo Clinic, Rochester, Minnesota, USA., Seetharam M; Mayo Clinic, Scottsdale, Arizona, USA., Birnbaum A; Rhode Island Hospital, Providence, Rhode Island, USA., Weickhardt A; Austin Health, Heidelberg, Victoria, Australia., Ganju V; Peninsula and Southeast Oncology, Frankston, Victoria, Australia., Joshua AM; Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia., Cavallo R; MacroGenics, Inc, Rockville, Maryland, USA., Peng L; MacroGenics, Inc, Rockville, Maryland, USA., Zhang X; MacroGenics, Inc, Rockville, Maryland, USA., Kaul S; AstraZeneca, Gaithersburg, Maryland, USA., Baughman J; MacroGenics, Inc, Rockville, Maryland, USA., Bonvini E; MacroGenics, Inc, Rockville, Maryland, USA., Moore PA; MacroGenics, Inc, Rockville, Maryland, USA., Goldberg SM; MacroGenics, Inc, Rockville, Maryland, USA., Arnaldez FI; MacroGenics, Inc, Rockville, Maryland, USA.; AstraZeneca, Gaithersburg, Maryland, USA., Ferris RL; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Lakhani NJ; START Midwest, Grand Rapids, Michigan, USA.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Apr; Vol. 10 (4).